Abstract: Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.
Type:
Application
Filed:
October 24, 2006
Publication date:
January 19, 2012
Applicant:
CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON INC
Inventors:
Douglas W. Losordo, David A. Goukassian
Abstract: Methods and products for identifying subjects at risk of acute kidney injury (AKI) are provided according to the invention. Included, for instance, are diagnostic kits and methods involving the use of at least two AKI associated markers.
Type:
Application
Filed:
September 18, 2008
Publication date:
March 10, 2011
Applicants:
Caritas St. Elizabeth's Medical Center of Boston, Inc., New York Medical College
Inventors:
Orfeas Liangos, Francesco Addabbo, Michael Goligorsky, Bertrand L. Jaber
Abstract: Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided.
Type:
Application
Filed:
June 30, 2009
Publication date:
June 24, 2010
Applicant:
Caritas St. Elizabeth Medical Center of Boston, Inc.
Abstract: As described below, the present invention features compositions and methods for increasing TNFR2/p75 receptor signaling to reduce inflammation. Methods for increasing TNFR2/p75 expression or signaling may also be used to increase the survival of resident cells or transplanted stem cells (e.g., bone marrow derived or peripheral blood derived stem cells) in a damaged tissue.
Type:
Application
Filed:
October 31, 2007
Publication date:
June 17, 2010
Applicant:
CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON, IN
Abstract: The present invention features compositions and methods of treating or preventing hypertension or a cardiac indication. In particular embodiments, the invention provides E2F2 as a new therapeutic target for the treatment of hypertension or a cardiac indication, and methods of increasing the expression and/or activity of E2F2.
Type:
Application
Filed:
October 29, 2007
Publication date:
May 27, 2010
Applicant:
Caritas St. Elizabeth Medical Center of Boston,Inc
Abstract: The present invention generally provides compositions and methods that are useful for the treatment or prevention of a neoplasm, and screening methods that can be used to detect compounds that modulate the activity of a DJ-I gene.
Type:
Application
Filed:
May 8, 2006
Publication date:
February 25, 2010
Applicant:
Caritas St. Elizabeth Medical Center of Boston Inc.
Abstract: The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof.
Type:
Application
Filed:
March 24, 2006
Publication date:
February 4, 2010
Applicant:
Caritas St. Elizabeth Medical Center of Boston Inc
Abstract: According to aspects of the invention, methods for preventing or treating kidney damage are provided. Compositions for the prevention or treatment of kidney damage are also provided. Aspects of the invention relate to methods for screening the toxicity of a radio-contrast agent. Kits for the treatment or prevention of kidney damage are also provided.
Type:
Application
Filed:
December 7, 2007
Publication date:
January 7, 2010
Applicant:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Inventors:
Alexey Y. Kolyada, Bertrand L. Jaber, Orfeas Liangos, Nicolaos E. Madias
Abstract: Tumors can be directed into a vasculogenic program and used to regenerate tissues in a verterbrate host, identify factors originating from the tumor that are useful for tissue regeneration, and to generate such factors for use in a subject apart from the tumor itself.
Type:
Grant
Filed:
October 18, 2006
Date of Patent:
December 29, 2009
Assignee:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Abstract: The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor cells (EPCs), bone marrow-derived stem cells (BMSCs), or both cell types. The invention has a wide spectrum of applications including reducing or eliminating tissue ischemia, especially tissue ischemia associated with a myocardial infarct (heart attack).
Type:
Application
Filed:
October 18, 2006
Publication date:
September 3, 2009
Applicant:
Caritas St.Elizabeth Medical Center of Boston, Inc
Abstract: The invention features compositions and methods that are useful for preventing or treating a cardiac disease or for promoting cardiac health following a myocardial infarction. The invention further features compositions and methods for promoting angiogenesis, cell proliferation, and/or decreasing apoptosis in muscle tissue, such as cardiac tissue. The invention provides for the expression of human growth hormone in cardiac muscle following a myocardial infarction.
Type:
Application
Filed:
March 23, 2007
Publication date:
April 23, 2009
Applicant:
Caritas St. Elizabeth Medical Center of Boston, Inc.
Abstract: The invention generally provides screening methods for the identification of therapeutic compounds useful for the treatment of a neurodegenerative disease, and related prophylactic and therapeutic compositions and methods.
Type:
Application
Filed:
October 20, 2006
Publication date:
January 22, 2009
Applicant:
Caritas St. Elizabeth Medical Center of Boston, Inc.
Abstract: This invention relates to methods and compositions for the treatment of apoptotic cell-death. In particular the invention relates to Akt molecules and their use in inhibiting apoptotic cell-death in cardiomyocytes, skeletal myocytes and/or vascular endothelial cells. In view of these discoveries, Akt molecules can be used to inhibit apoptotic cell-death of any of the foregoing cells, and in particular, to treat conditions (e.g., myocardial infarction) that result in increased apoptotic cell-death of cardiomyocytes, skeletal myocytes and/or vascular endothelial cells.
Type:
Grant
Filed:
September 29, 1999
Date of Patent:
May 6, 2008
Assignee:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Abstract: Tumors can be directed into a vasculogeinc program and used to regenerate tissues in a verterbrate host, identify factors originating from the tumor that are useful for tissue regeneration, and to generate such factors for use in a subject apart from the tumor itself.
Type:
Application
Filed:
October 18, 2006
Publication date:
May 3, 2007
Applicant:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Abstract: A non-invasive method and system for assessing intraocular pressure (ICP) is disclosed. The method comprises the steps of measuring venous outflow pressure (VOP) using a venous ophthalmodynamometer device (vODM); measuring ophthalmic r central retinal arterial blood flow using color Doppler imaging device; and then estimating ICP using venous outflow data from the vODM and pulsatility and/or resistivity relationships derived from the Doppler imaging data. Further disclosed is a novel vODM for measuring VOP in low flow veins.
Type:
Grant
Filed:
May 12, 2003
Date of Patent:
October 17, 2006
Assignee:
Caritas St. Elizabeth Medical Center of Boston, Inc.
Abstract: The present invention generally provides methods for preventing or treating tissue ischemia using CXCR4 antagonists. In one embodiment, the methods include administering to a mammal a therapeutically effective amount of a particular bicylic polyamine to elevate peripheral blood EPCs. The invention has a wide spectrum of applications including reducing or eliminating tissue ishemica associated with a myocardial infarct (heart attack).
Type:
Application
Filed:
December 28, 2005
Publication date:
August 31, 2006
Applicant:
Caritas St. Elizabeth Medical Center of Boston, Inc.
Inventors:
Douglas Losordo, Gary Bridger, Jeffrey Isner, Linda Isner
Abstract: The present invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability.
Type:
Application
Filed:
October 3, 2003
Publication date:
July 27, 2006
Applicant:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Abstract: Compositions comprising 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivatives thereof for the treatment of depression are disclosed.
Type:
Grant
Filed:
March 18, 2003
Date of Patent:
February 1, 2005
Assignee:
Caritas St. Elizabeth's Medical Center of Boston, Inc.
Inventors:
Gregory F. Oxenkrug, Nikolai S. Zefirov, Sergey O. Bachurin
Abstract: This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.
Type:
Application
Filed:
November 14, 2003
Publication date:
June 24, 2004
Applicant:
Caritas St. Elizabeth's Medical Center of Boston, Inc.